Drug intelligence / Profile preview

lencanavir

Development stage: Preclinical
Lead developer: Gilead Sciences
Administration: Injection

Overview

Lencanavir is an investigational drug administered via injection, currently being studied for the nursing care of patients with mild cognitive impairment and mild dementia caused by Alzheimer's disease (AD). Alzheimer's disease is characterized by the deposition of amyloid beta (Aβ) plaques in the brain and the formation of neurofibrillary tangles due to excessive phosphorylation of tau protein, leading to memory impairment, aphasia, loss of function, dementia, and impairment of visual spatial ability, often accompanied by changes in personality and behavior.

Targets

p24 (HIV-1 capsid protein p24)

Beyond the preview

Go deeper on lencanavir.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on lencanavir.

Explore the full profile